These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26114404)

  • 1. Novel Therapy With Ramelteon for Hypoactive Delirium: A Case Report.
    Miura S; Furuya M; Yasuda H; Miyaoka T; Horiguchi J
    J Clin Psychopharmacol; 2015 Oct; 35(5):616-8. PubMed ID: 26114404
    [No Abstract]   [Full Text] [Related]  

  • 2. A Case of Unilateral Hypnic Headache: Rapid Response to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist.
    Arai M
    Headache; 2015; 55(7):1010-1. PubMed ID: 26121162
    [No Abstract]   [Full Text] [Related]  

  • 3. [A novel therapeutic drug: ramelteon].
    Miyamoto M
    Nihon Rinsho; 2009 Aug; 67(8):1595-600. PubMed ID: 19768947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ramelteon: TAK 375.
    Drugs R D; 2005; 6(3):186-8. PubMed ID: 15869323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune hepatitis in association with ramelteon.
    Fourman LT; Robert Meyer B
    J Clin Gastroenterol; 2013 Aug; 47(7):651-4. PubMed ID: 23632362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fresh from the pipeline: Ramelteon.
    Buysse D; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Nov; 4(11):881-2. PubMed ID: 16299918
    [No Abstract]   [Full Text] [Related]  

  • 7. A Cluster Headache Responsive to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist.
    Imai N
    Intern Med; 2016; 55(17):2483-5. PubMed ID: 27580554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
    Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramelteon for the treatment of delirium in elderly patients: a consecutive case series study.
    Tsuda A; Nishimura K; Naganawa E; Otsubo T; Ishigooka J
    Int J Psychiatry Med; 2014; 47(2):97-104. PubMed ID: 25084796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramelteon and improved insomnia in alcohol-dependent patients: a case series.
    Brower KJ; Conroy DA; Kurth ME; Anderson BJ; Stein MD
    J Clin Sleep Med; 2011 Jun; 7(3):274-5. PubMed ID: 21677897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melatonin receptor agonist ramelteon activates the extracellular signal-regulated kinase 1/2 in mouse cerebellar granule cells.
    Imbesi M; Uz T; Manev H
    Neuroscience; 2008 Sep; 155(4):1160-4. PubMed ID: 18664376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells.
    Osanai K; Kobayashi Y; Otsu M; Izawa T; Sakai K; Iwashita M
    Hum Cell; 2017 Jul; 30(3):209-215. PubMed ID: 28382516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Delirium, insomnia in hospitalization and ramelteon].
    Ito T
    Nihon Rinsho; 2012 May; 70(5):907-13. PubMed ID: 22620020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trial.
    Mahableshwarkar AR; Calabrese JR; Macek TA; Budur K; Adefuye A; Dong X; Hanson E; Sachs GS
    J Affect Disord; 2017 Oct; 221():275-282. PubMed ID: 28662460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of M-II, the major human metabolite of ramelteon.
    Nishiyama K; Nishikawa H; Kato K; Miyamoto M; Tsukamoto T; Hirai K
    Pharmacology; 2014; 93(3-4):197-201. PubMed ID: 24923230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice.
    Miyamoto M
    Neurosci Lett; 2006 Jul; 402(3):201-4. PubMed ID: 16730121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ramelteon: profile of a new sleep-promoting medication.
    Owen RT
    Drugs Today (Barc); 2006 Apr; 42(4):255-63. PubMed ID: 16703122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2.
    Greenblatt DJ; Harmatz JS; Karim A
    J Clin Pharmacol; 2007 Apr; 47(4):485-96. PubMed ID: 17389558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.
    Miyamoto M
    CNS Neurosci Ther; 2009; 15(1):32-51. PubMed ID: 19228178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked improvement in delirium with ramelteon: five case reports.
    Furuya M; Miyaoka T; Yasuda H; Yamashita S; Tanaka I; Otsuka S; Wake R; Horiguchi J
    Psychogeriatrics; 2012 Dec; 12(4):259-62. PubMed ID: 23279149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.